CO090 | DIRECT ORAL ANTICOAGULANTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE INHERITED THROMBOPHILIA: A REAL-WORLD MULTICENTER STUDY
Abstract
Introduction. The role of direct oral anticoagulants (DOACs) in the management of patients with venous thromboembolism (VTE) and severe inherited thrombophilia is controversial. Aims. To evaluate the effectiveness and safety of DOACs in VTE patients with severe thrombophilia. Patients and methods. Consecutive patients with a history of VTE and severe thrombophilia [AT, PS, PC deficiency, FV Leiden (FVL) homozygosis, FIIG20210A homozygosis, combined heterozygosis of FVL+ FIIG20210A, and homocystinuria] referred between March 2014 and November 2025 to five tertiary thrombosis centers were included. All patients were treated with DOACs for at least 3 months. Each patient underwent follow-up every 3 months. Results. A total of 100 patients were included. During follow-up, three recurrent VTE events (3%) occurred, corresponding to an incidence rate of 0.49 events per 100 patient-years (95% CI 0.10–1.43). No recurrences were observed within the first 3 months of treatment. Notably, recurrent events occurred in the presence of major transient prothrombotic conditions (pregnancy or active cancer). No major bleeding events were recorded. Minor bleeding occurred in 3% of patients, and clinically relevant non-major bleeding in 1%. Conclusions. In this multicenter real-world cohort of patients with severe inherited thrombophilia, long-term DOAC therapy was associated with a low recurrence rate and a favorable safety profile. These findings provide clinically relevant reassurance supporting the use of DOACs for secondary prevention of VTE in carefully selected patients with severe inherited thrombophilia.
Related
- Decision dilemmas and insights in secondary prevention of ischemic stroke: a case report of an elderly patient with hereditary thrombophilia and high-risk patent foramen ovale
- Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
- Antithrombotic Therapy for Secondary Stroke Prevention in Patients With Symptomatic Large‐Artery Atherosclerosis and Atrial Fibrillation: A Multicenter Experience
- Long-Term Effectiveness and Safety of Direct Oral Anticoagulants in Japanese Patients With Venous Thromboembolism ― Extended Follow-up Results From the KUROSIO Study ―
- PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
BibTeX
@article{tufano2026co090,
title = {{CO090 | DIRECT ORAL ANTICOAGULANTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE INHERITED THROMBOPHILIA: A REAL-WORLD MULTICENTER STUDY}},
author = {Antonella Tufano},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/792},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO090 | DIRECT ORAL ANTICOAGULANTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE INHERITED THROMBOPHILIA: A REAL-WORLD MULTICENTER STUDY
AU - Antonella Tufano
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/792
AB - Introduction. The role of direct oral anticoagulants (DOACs) in the management of patients with venous thromboembolism (VTE) and severe inherited thrombophilia is controversial. Aims. To evaluate the effectiveness and safety of DOACs in VTE patients with severe thrombophilia. Patients and methods. Consecutive patients with a history of VTE and severe thrombophilia [AT, PS, PC deficiency, FV Leiden (FVL) homozygosis, FIIG20210A homozygosis, combined heterozygosis of FVL+ FIIG20210A, and homocystinuria] referred between March 2014 and November 2025 to five tertiary thrombosis centers were included. All patients were treated with DOACs for at least 3 months. Each patient underwent follow-up every 3 months. Results. A total of 100 patients were included. During follow-up, three recurrent VTE events (3%) occurred, corresponding to an incidence rate of 0.49 events per 100 patient-years (95% CI 0.10–1.43). No recurrences were observed within the first 3 months of treatment. Notably, recurrent events occurred in the presence of major transient prothrombotic conditions (pregnancy or active cancer). No major bleeding events were recorded. Minor bleeding occurred in 3% of patients, and clinically relevant non-major bleeding in 1%. Conclusions. In this multicenter real-world cohort of patients with severe inherited thrombophilia, long-term DOAC therapy was associated with a low recurrence rate and a favorable safety profile. These findings provide clinically relevant reassurance supporting the use of DOACs for secondary prevention of VTE in carefully selected patients with severe inherited thrombophilia.
SN - 2785-5309
ER -